EMG
ABCL icon

ETF Managers Group’s AbCellera Biologics ABCL Stock Holding History

ETF Managers Group’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$713K Buy
+94,496
New +$858K 0.02% 326
2022
Q4 		– Sell
-84,143
Closed -$832K – 515
2022
Q3 		$832K Sell
84,143
-5,752
-6% -$63.1K 0.03% 233
2022
Q2 		$909K Buy
89,895
+3,772
+4% +$31.9K 0.03% 245
2022
Q1 		$840K Buy
86,123
+1,018
+1% +$9.64K 0.02% 328
2021
Q4 		$1.22M Sell
85,105
-16,659
-16% -$253K 0.02% 252
2021
Q3 		$1.98M Buy
101,764
+21,792
+27% +$385K 0.04% 202
2021
Q2 		$1.7M Buy
79,972
+7,348
+10% +$203K 0.03% 238
2021
Q1 		$1.94M Buy
+72,624
New +$2.89M 0.03% 193

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return